136 related articles for article (PubMed ID: 27768092)
1. Prevalence, incidence and survival of smoldering multiple myeloma in the United States.
Ravindran A; Bartley AC; Holton SJ; Gonsalves WI; Kapoor P; Siddiqui MA; Hashmi SK; Marshall AL; Ashrani AA; Dispenzieri A; Kyle RA; Rajkumar SV; Go RS
Blood Cancer J; 2016 Oct; 6(10):e486. PubMed ID: 27768092
[No Abstract] [Full Text] [Related]
2. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
[No Abstract] [Full Text] [Related]
3. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
[No Abstract] [Full Text] [Related]
4. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Magnano L; Tovar N; Rodríguez-Lobato LG; Calvo X; Aróstegui JI; Díaz T; Lozano E; Rozman M; Yagüe J; Bladé J; Rosiñol L
Leukemia; 2018 Jun; 32(6):1427-1434. PubMed ID: 29463830
[TBL] [Abstract][Full Text] [Related]
5. Smoldering Myeloma Treatment: Who, What, and When.
Mejia Saldarriaga M; Rossi A
Cancer J; 2021 May-Jun 01; 27(3):185-189. PubMed ID: 34549905
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N
Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308
[No Abstract] [Full Text] [Related]
7. Population screening for smoldering multiple myeloma reveals high prevalence.
Nat Med; 2023 Feb; 29(2):313-314. PubMed ID: 36755165
[No Abstract] [Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
Maciocia N; Wechalekar A; Yong K
Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
[TBL] [Abstract][Full Text] [Related]
9. Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV; González-Calle V
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
[TBL] [Abstract][Full Text] [Related]
10. Clinical Controversies in the Management of Smoldering Multiple Myeloma.
Lomas OC; Ghobrial IM
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-6. PubMed ID: 32223666
[TBL] [Abstract][Full Text] [Related]
11. Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma.
Francis ER; Chen F; Kidacki M; Miller R; Alkhasoneh M; Talamo G; Straub M; Klinefelter K; Kodali N; Zhu Y
Clin Chim Acta; 2018 Dec; 487():306-308. PubMed ID: 30315756
[TBL] [Abstract][Full Text] [Related]
12. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.
Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J
Med Clin (Barc); 2017 Jun; 148(11):517-523. PubMed ID: 28341370
[No Abstract] [Full Text] [Related]
13. [Recurrent invasive pneumococcal disease in a patient with IgG-κ smoldering multiple myeloma].
Chiba M; Oshimi K; Matsukawa T; Okada K; Miyagishima T
Rinsho Ketsueki; 2018; 59(1):40-44. PubMed ID: 29415936
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling in plasma cell disorders: a feasibility study.
Mailankody S; Devlin SM; Korde N; Lendvai N; Lesokhin A; Landau H; Hassoun H; Ballagi A; Ekman D; Chung DJ; Patel M; Koehne G; Giralt S; Landgren O
Leuk Lymphoma; 2017 Jul; 58(7):1757-1759. PubMed ID: 27908223
[No Abstract] [Full Text] [Related]
15. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
[No Abstract] [Full Text] [Related]
16. Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades.
Kyle RA; Therneau TM; Rajkumar SV; Larson DR; Plevak MF; Melton LJ
Cancer; 2004 Dec; 101(11):2667-74. PubMed ID: 15481060
[TBL] [Abstract][Full Text] [Related]
17. Timing of treatment of smoldering myeloma: early treatment.
Mateos MV; González-Calle V
Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
Muchtar E; Kumar SK; Magen H; Gertz MA
Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
[TBL] [Abstract][Full Text] [Related]
19. [CME: Multiple Myeloma - a Review].
Bräutigam M; Biskup E
Praxis (Bern 1994); 2018 Jul; 107(14):749-754. PubMed ID: 29969971
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Wu V; Moshier E; Leng S; Barlogie B; Cho HJ; Jagannath S; Madduri D; Mazumdar M; Parekh S; Chari A
Blood Adv; 2018 Jun; 2(12):1470-1479. PubMed ID: 29945937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
